Paper37665348
E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
Liu Y and 3 others. Ann Hematol, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia. Papers, record 37665348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37665348
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytarabine | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Remission Induction | |
| Prognosis | |
| Polymorphism, Single Nucleotide | |
| E2F1 Transcription Factor |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2021JJ41011 | Natural Science Foundation of Hunan Province | PubMed |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32014868 | Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32014868 | PubMed |
| 2 | 31101526 | Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. | Blood Rev | 2019 | https://conductscience.org/library/papers/31101526 | PubMed |
| 3 | 33328603 | Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. | Leukemia | 2021 | https://conductscience.org/library/papers/33328603 | PubMed |
| 4 | 27381050 | Pharmacogenomics and the treatment of acute myeloid leukemia. | Pharmacogenomics | 2016 | https://conductscience.org/library/papers/27381050 | PubMed |
| 5 | 30088438 | Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. | Pharmacogenomics | 2018 | https://conductscience.org/library/papers/30088438 | PubMed |
| 6 | 31950591 | Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. | EMBO Mol Med | 2020 | https://conductscience.org/library/papers/31950591 | PubMed |
| 7 | 28068326 | KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. | Oncogene | 2017 | https://conductscience.org/library/papers/28068326 | PubMed |
| 8 | 33665206 | E2F1: Cause and Consequence of DNA Replication Stress. | Front Mol Biosci | 2020 | https://conductscience.org/library/papers/33665206 | PubMed |
| 9 | 28797284 | Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2). | J Exp Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28797284 | PubMed |
| 10 | 29631596 | Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). | J Transl Med | 2018 | https://conductscience.org/library/papers/29631596 | PubMed |
| 11 | 14673054 | Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/14673054 | PubMed |
| 12 | 29299175 | Single nucleotide polymorphisms and cancer susceptibility. | Oncotarget | 2017 | https://conductscience.org/library/papers/29299175 | PubMed |
| 13 | 26398894 | Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer? | Crit Rev Clin Lab Sci | 2016 | https://conductscience.org/library/papers/26398894 | PubMed |
| 14 | 32186770 | MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression. | Oncol Rep | 2020 | https://conductscience.org/library/papers/32186770 | PubMed |
| 15 | 32951317 | Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region. | J Cell Mol Med | 2020 | https://conductscience.org/library/papers/32951317 | PubMed |
| 16 | 31870703 | The conflicting role of E2F1 in prostate cancer: A matter of cell context or interpretational flexibility? | Biochim Biophys Acta Rev Cancer | 2020 | https://conductscience.org/library/papers/31870703 | PubMed |
| 17 | 30590814 | ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30590814 | PubMed |
| 18 | 35927248 | ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1. | Oncogenesis | 2022 | https://conductscience.org/library/papers/35927248 | PubMed |
| 19 | 8653789 | Tumor induction and tissue atrophy in mice lacking E2F-1. | Cell | 1996 | https://conductscience.org/library/papers/8653789 | PubMed |
| 20 | 9774967 | Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. | Mol Cell | 1998 | https://conductscience.org/library/papers/9774967 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 38676765 | GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy. | Ann Hematol | 2024 | https://conductscience.org/library/papers/38676765 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| E2F1 | 1869 | PubTator's text mining | https://conductscience.org/library/genes/1869 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37665348
GET https://conductscience.org/api/papers/v1/37665348/references?page=2